Kiromic Biopharma, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -0.99%724.652.6%$747.27m
AMGNAmgen, Inc. 0.12%231.221.4%$609.24m
BIIBBiogen, Inc. -0.61%260.671.8%$576.53m
MRNAModerna, Inc. -3.62%120.620.0%$568.58m
GILDGilead Sciences, Inc. -0.12%64.871.0%$549.37m
VRTXVertex Pharmaceuticals, Inc. -0.15%298.181.9%$429.27m
ILMNIllumina, Inc. -1.92%208.643.2%$402.96m
SNSSSunesis Pharmaceuticals, Inc. 1.24%4.070.7%$284.51m
SAVACassava Sciences, Inc. -5.50%40.020.0%$179.24m
BNTXBioNTech SE -0.72%136.540.0%$108.61m
TECHBio-Techne Corp. -4.39%295.504.5%$96.34m
BMRNBioMarin Pharmaceutical, Inc. -3.21%88.544.2%$92.84m
PRTAProthena Corp. Plc -2.36%57.1913.8%$77.35m
CRSPCRISPR Therapeutics AG -3.98%62.660.6%$75.10m
NVAXNovavax, Inc. -8.25%16.5975.6%$72.94m

Company Profile

Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. Its platform, DIAMOND AI, discovers, validates, and develops cell and gene therapies with a therapeutic focus on immuno-oncology. The company is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.